



IPO INSIGHTS



Yatharth Hospital and Trauma Care Services Limited

Issue Dates - Opens:26-07-2023 | Closes: 28-07-2023

IPO Note	<ol style="list-style-type: none"> 1. Yatharth Hospital and Trauma Care Services Limited is a multi-care hospital chain. 2. Among the top 10 largest private hospitals in NCR Delhi. 3. Offers healthcare services across numerous specialties and super specialties Centres of Excellence (COE). 4. Yatharth Hospital and Trauma Care Services Limited operates three super specialty hospitals in the Delhi NCR region, providing a wide range of healthcare services with a focus on various specialties and super specialties.
Rating	★★★ (Good)

IPO SNAPSHOT

Issue Size	-
Issue Type	Book Built IPO
Fresh Issue	₹490 Crores
Offer for Sale	-
Face Value Per Share	₹ 10
Price Band Per Share	₹285 to ₹300
Minimum Lot Size	50 shares
Listing On	BSE, NSE
Registrar to the Issue	Link Intime India Private Ltd

IPO SNAPSHOT – Yatharth Hospital and Trauma Care Services Limited

About the Company	<ul style="list-style-type: none"> Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospital chain. They rank among the top 10 largest private hospitals in the National Capital Region of Delhi. Yatharth Hospital presently operates three super specialty hospitals situated in Delhi NCR, at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. Noida Extension Hospital has 450 beds and is one of the largest hospitals around the area. A team of 370 doctors is engaged with the company. They offer healthcare services across numerous specialties and super specialties. The super specialty or Centres of Excellence (COE) of the hospital includes: Centre of Medicine, Centre of General Surgery, Centre of Gastroenterology, Centre of Cardiology, Centre of Nephrology & Urology, Centre of Pulmonology, Centre of Neurosciences, Centre of Paediatrics, Centre of Gynaecology, Centre of Orthopaedics and Spine & Rheumatology. 																														
Competitive Strengths	<ul style="list-style-type: none"> Among the leading super-specialty hospital in Delhi NCR with diverse specialty and payer mix. Advanced and high-end medical equipment and technology. Company has own catheterization Laboratory and computerized Tomography scan. Experienced and qualified professional management team with strong execution track record. Track record of stable operating and financial performance and growth. 																														
Financials (₹ in Crore)	<table border="1"> <thead> <tr> <th>Particulars</th> <th>31-3-2021</th> <th>31-3-2022</th> <th>31-3-2023</th> <th>Y-o-Y</th> </tr> </thead> <tbody> <tr> <td>Revenue from Operations</td> <td>228.67</td> <td>400.93</td> <td>520.29</td> <td>30%</td> </tr> <tr> <td>EBITDA</td> <td>67.01</td> <td>110.81</td> <td>133.76</td> <td>21%</td> </tr> <tr> <td>EBITDA Margin</td> <td>29.3%</td> <td>27.6%</td> <td>25.7%</td> <td></td> </tr> <tr> <td>Profit After Tax</td> <td>19.58</td> <td>44.16</td> <td>65.76</td> <td>49%</td> </tr> <tr> <td>Profit After Tax Margin</td> <td>8.6%</td> <td>11%</td> <td>12.6%</td> <td></td> </tr> </tbody> </table>	Particulars	31-3-2021	31-3-2022	31-3-2023	Y-o-Y	Revenue from Operations	228.67	400.93	520.29	30%	EBITDA	67.01	110.81	133.76	21%	EBITDA Margin	29.3%	27.6%	25.7%		Profit After Tax	19.58	44.16	65.76	49%	Profit After Tax Margin	8.6%	11%	12.6%	
Particulars	31-3-2021	31-3-2022	31-3-2023	Y-o-Y																											
Revenue from Operations	228.67	400.93	520.29	30%																											
EBITDA	67.01	110.81	133.76	21%																											
EBITDA Margin	29.3%	27.6%	25.7%																												
Profit After Tax	19.58	44.16	65.76	49%																											
Profit After Tax Margin	8.6%	11%	12.6%																												
Valuation	<ul style="list-style-type: none"> Attributing Annualized FY23 Earnings asking P/E = 29.73 																														
Peers	<table border="1"> <thead> <tr> <th>Company Name</th> <th>P/E ratio</th> </tr> </thead> <tbody> <tr> <td>Apollo Hospitals Enterprise Limited</td> <td>89.44</td> </tr> <tr> <td>Fortis Healthcare Limited</td> <td>40.36</td> </tr> <tr> <td>Narayana Hrudalaya Limited</td> <td>33.29</td> </tr> <tr> <td>Max Healthcare Institute Limited</td> <td>52.66</td> </tr> <tr> <td>Krishna Institute of Medical Sciences Limited</td> <td>42.44</td> </tr> <tr> <td>Healthcare Global Enterprises Limited</td> <td>151.02</td> </tr> <tr> <td>Global Health Limited</td> <td>52.44</td> </tr> </tbody> </table>	Company Name	P/E ratio	Apollo Hospitals Enterprise Limited	89.44	Fortis Healthcare Limited	40.36	Narayana Hrudalaya Limited	33.29	Max Healthcare Institute Limited	52.66	Krishna Institute of Medical Sciences Limited	42.44	Healthcare Global Enterprises Limited	151.02	Global Health Limited	52.44														
Company Name	P/E ratio																														
Apollo Hospitals Enterprise Limited	89.44																														
Fortis Healthcare Limited	40.36																														
Narayana Hrudalaya Limited	33.29																														
Max Healthcare Institute Limited	52.66																														
Krishna Institute of Medical Sciences Limited	42.44																														
Healthcare Global Enterprises Limited	151.02																														
Global Health Limited	52.44																														
Promoter	<ul style="list-style-type: none"> AJAY KUMAR TYAGI KAPIL KUMAR 																														
Objects of the issue	<ul style="list-style-type: none"> Repayment in full or part debt of the company Investing in the expansion of the company Utilization of funds for Potential acquisitions and strategic initiatives to grow the business General corporate purposes 																														

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

